Research and Markets: Colon Cancer Global Clinical Trials Review, Q4, 2010

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/1e1239/colon_cancer_globa) has announced the addition of GlobalData 's new report "Colon Cancer Global Clinical Trials Review, Q4, 2010" to their offering.

Colon Cancer Global Clinical Trials Review, Q4, 2010 provides data on the Colon Cancer clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Colon Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the status of participation by the developing nations. It offers coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating Colon Cancer.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Scope

  • Data on the number of clinical trials conducted in North America, South And Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status and trial success rate
  • Review of key discontinued trials (suspended, withdrawn and terminated)
  • Overview of the enrollment pattern by phase for the past decade
  • Number of clinical trials segmented by key drugs
  • Clinical trial overview of top 20 companies, which include Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, and so on.
  • Clinical trial overview of top 20 Universities / Institutes / Hospitals including National Cancer Institute, Cancer Research UK, Cancer Research Institute , and others

Key Topics Covered:

  • 1.1. List of Tables
  • 1.2. List of Figures
  • 2. Introduction
  • 3. Clinical Trials by Region
  • 4. Clinical Trials by Phase
  • 5. Clincial Trials by Trial Status
  • 6. Subjects Recruited Over a period
  • 7. Prominent Sponsors
  • 8. Prominent Drug Comparision
  • 9. Clinical Trial Profiles
  • 10. Appendix

For more information visit http://www.researchandmarkets.com/research/1e1239/colon_cancer_globa



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.